Clik here to view.
Mevion下一代质子治疗系统治疗首例患者
马萨诸塞州利特尔顿 (美国商业资讯) — Mevion Medical Systems宣布，华盛顿特区MedStar乔治敦大学医院在全球率先采用MEVION S250i质子治疗系统®治疗患者。 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20180403005749/zh-CN/ The MEVION S250i...
View ArticleClik here to view.
Terns Pharmaceuticals获得礼来公司(Eli Lilly and Company)三项NASH资产的全球独家开发和商业化权益
加州圣马特奥 (美国商业资讯) — Terns Pharmaceuticals...
View ArticleClik here to view.
Terns Pharmaceuticals Acquires Global, Exclusive Rights to Develop and...
SAN MATEO, Calif. Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small molecule drugs to treat liver disease and...
View ArticleClik here to view.
Samsung Bioepis Settles Patent Disputes with AbbVie, Clearing the Way for the...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that it has signed a licensing agreement with AbbVie Inc., settling all pending patent litigation between the two companies and clearing the...
View ArticleClik here to view.
FIMECS, Inc. Concludes Licensing Agreement with Takeda to Develop Novel...
KANAGAWA, Japan FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on protein degradation, today announced it has concluded a strategic licensing agreement...
View ArticleClik here to view.
Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize...
TOKYO Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced the company will partner with Mylan N.V. (NASDAQ:MYL) to commercialize FKB327, a biosimilar to Humira® (adalimumab) developed by...
View ArticleClik here to view.
CANbridge Receives Approval to Commence CAN008 Phase II/III Trial in...
BEIJING, China CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that the China Food and Drug Administration...
View ArticleClik here to view.
Sosei Confirms New Data Demonstrating AZD4635, a Novel A2A Receptor...
TOKYO & LONDON Sosei Group Corporation (“Sosei” or the “Company”; TSE Mothers Index: 4565), the world leader in GPCR medicine design and development, announces that new preclinical data for...
View ArticleClik here to view.
Certara社がマーケットアクセス、医療経済・アウトカム研究（HEOR）およびリアルワールドエビデンスソリューション分野のリーダーであるAnalytic...
ニュージャージー州プリンストン （ビジネスワイヤ） — モデルを活かした医薬品開発とレギュラトリーサイエンスのグローバルリーダーであるCertara®社は本日、医療経済・アウトカム研究（HEOR）とリアルワールドデータの活用を通して、医薬品および医療技術の価値に関する最高水準の科学的エビデンスを提供することを目指すグローバルコンサルティンググループAnalytica...
View ArticleClik here to view.
和铂医药与科伦博泰开展全球合作，共同开发多个创新全人源抗体药物
中国上海、成都，荷兰鹿特丹，美国波士顿、新泽西 和铂医药（Harbour BioMed）与专注于创新药物研发的四川科伦博泰生物医药股份有限公司（Kelun-Biotech）宣布达成全球战略合作，共同研究、开发和商业化新型全人源抗体药物。作为合作的一部分，双方已利用和铂医药的全人源转基因小鼠抗体平台，正在开展针对肿瘤和自身免疫等重大疾病的多个靶点的抗体研发项目。...
View ArticleClik here to view.
MOLOGEN AG: Collaboration with licensing partner ONCOLOGIE gains momentum
BERLIN The biopharmaceutical company MOLOGEN AG announced today that the collaboration with ONCOLOGIE, agreed on in February 2018, is making good progress. The collaboration includes a license...
View ArticleClik here to view.
EpimAb Biotherapeutics and Zhejiang Teruisi Biopharmaceutical Announce...
SHANGHAI & SUZHOU & HUZHOU, China EpimAb Biotherapeutics, a Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and Zhejiang Teruisi Biopharmaceutical, a company...
View ArticleClik here to view.
CBT Pharmaceuticals and CrystalGenomics Announce Partnership for...
PLEASANTON, Calif. & SEOUL, South Korea CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of...
View ArticleClik here to view.
GNI Group Initiates Phase I Study of F351 in USA
TOKYO GNI USA, Inc., a wholly-owned subsidiary of GNI Group Ltd. (TOKYO:2160), announced the first subject was dosed in the F351 Phase I clinical trial taking place in New Jersey, USA. The primary...
View ArticleClik here to view.
Astellas Reports Financial Results for FY2017
TOKYO Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced the financial results for fiscal year 2017 ending March 31, 2018 (“FY2017”). “Key global...
View ArticleClik here to view.
Foundation Medicine, Roche and DIAN Diagnostics Collaborate to Advance...
CAMBRIDGE, Mass. Foundation Medicine, Inc., (NASDAQ:FMI), F. Hoffmann-La Roche Ltd (Roche) and DIAN Diagnostics Group, Co., Ltd. (DIAN), today announced a three-party collaboration to integrate...
View ArticleClik here to view.
Augmenix, Inc.、東京に日本拠点を開設
米マサチューセッツ州ベッドフォードおよび東京 （ビジネスワイヤ） — 放射線療法に伴う毒性を低減するハイドロゲル・スペーシング・ソリューションの世界的リーダーであるAugmenix, Inc.は、日本拠点としてオーグメニックス株式会社を開設しました。 この東京都心の新拠点から、日本全国のお客様にカスタマー・サポートを提供します。 オーグメニックス株式会社代表取締役社長の...
View ArticleClik here to view.
Augmenix, Inc. Announces the Opening of a New Headquarters in Tokyo, Japan
BEDFORD, Mass. & TOKYO Augmenix, Inc., a worldwide leader in hydrogel spacing solutions which reduces toxicity associated with radiation therapy, has opened a new company headquarters, Augmenix...
View ArticleClik here to view.
Helsinn Investment Fund, Bio Capital Impact Fund and Windham Venture Partners...
JERUSALEM NovellusDx, the leader in functional genomics, today announced it has completed an equity financing of $6 million. The financing round is with the participation of Helsinn Investment Fund...
View ArticleClik here to view.
迈博斯生物宣布完成4000万美元B轮融资，加速临床项目推进
中国， 苏州 (美国商业资讯)–迈博斯生物，一家处于临床研发阶段的抗体新药研发公司，近日宣布完成了由红杉资本中国基金领投的4000万美元的B轮融资。除了上轮投资者礼来亚洲基金和本轮领投方红杉中国外，迈博斯还新增了King Star 资本作为其投资人。该笔资金将用于公司处于临床阶段的第二代PD-L1抗体的临床开发，以及用于推进多个后续产品的临床申报。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View Article